Nuveen AMT-Free Municipal Credit Income Fund (NVG) Stock

Several Nuveen municipal bond closed-end funds aggressively raised distributions earlier this year, one of those funds being NVG. NVG's high leverage and potential mixture of lower credit quality exposure offer higher yields, but that does come with increased risks. Despite recent Fed rate cuts, coverage of the distribution is likely to remain weak, this is likely to lead to a mix of tax-free and tax-deferred income classified distributions.

Target enrollment in the chronic cohort close to completion Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) for its proprietary investigational lead compound, NVG-291, in individuals with spinal cord injury (SCI) is approaching completion. "We are excited to be near completion of enrollment in the chronic cohort of our Phase 1b/2a study in SCI," said Mike Kelly, NervGen's President & CEO.

New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). NVG-300 is a new biologic molecule discovered at NervGen.

The Nuveen AMT-Free Municipal Credit Income Fund is a popular CEF with over $4 billion in managed assets. NVG trades at a significant discount to NAV, but there are several negative factors that make it unattractive compared to other similar products. Negatives include a high expense ratio, weak historical risk-adjusted returns, and a high cost of leverage relative to underlying asset yield.